James Huang

Director James Huang buys 150,000 shares of CNTB at $2.48; stock now $2.15, down -43.7% from 52-week high amid revenue collapse of -99.8%.

James Huang (Director) purchased 150,000 shares at $2.48 on 2026-05-29, increasing his holdings from 13,160,000 to 13,310,000 shares. The stock has since declined to $2.15 (current price), representing a -13.0% drop over the past 30 days and -17.0% over 90 days. Most notably, the company's fundamentals are severely deteriorated: annual revenue growth stands at -99.8%, quarterly revenue is just $169,000.00, and the company posted a net loss of $-19,398,000.00 in its latest full fiscal year. Huang's prior buy at this ticker on 2026-03-31 produced 90-day returns of -32.2%, and across his broader cross-ticker track record (1 prior buy), his average 90-day return is -32.2% with a 0.00% win rate. This new purchase occurs against ongoing deterioration in both stock price and fundamental metrics.

Director James Huang sells 313,446 shares of ATRA at $10.10; stock now $8.34, -53.9% from 52-week high. Contrasts with 2 prior well-timed buys at this ticker.

James Huang, a Director, sold 313,446 shares at $10.10 on 2026-05-07, reducing his holdings by 23.7% from 1,324,446 to 1,011,000 shares. This sale occurred when the stock was trading significantly above its current price of $8.34, which is now -53.9% from the 52-week high of $18.09. Notably, Huang's prior trading history at ATRA shows two well-timed buy transactions (2025-08-15 and 2025-07-17), both of which yielded positive 90-day returns (+9.0% and +57.4% respectively), establishing a pattern of sound entry timing at this specific ticker. The current price decline relative to the sale price, combined with his proven ability to identify opportune entry points at ATRA, raises questions about whether this sell was discretionary or driven by non-discretionary factors, and whether the subsequent 30-day +66.5% and 90-day +70.9% gains (from the current perspective) represent a significant misstep in exit timing.

Director Huang James buys 1,160,000 shares of CNTB at $3.45 for $4,002,000, raising stake to 13,160,000 shares amid severe revenue collapse (-99.8%) and ongoing losses ($-17.2M).

Director Huang James purchased 1,160,000 shares at $3.45 on 2026-03-31, increasing his holdings by 9.7% to 13,160,000 shares. This $4,002,000 acquisition occurred when the stock trades at $2.72 (26.3% below its 52-week high of $3.69), suggesting the purchase price was above current levels. The company faces severe operational stress: latest quarterly revenue stood at $16,000, representing a -99.8% annual revenue decline, with net losses of $-17.2M over the most recent full fiscal year. An insider director acquiring a material stake while the company experiences near-complete revenue collapse and substantial ongoing losses is noteworthy and merits scrutiny of the underlying business dynamics and recovery thesis.

Director James Huang purchases 55,000 shares of ATRA at $12.19; holdings rise to 1,405,000 shares

Director James Huang purchased 55,000 shares on 2025-08-15 at $12.19 per share, increasing his holdings from 1,350,000 shares to 1,405,000 shares—a net addition of 55,000 shares representing a 4.1% increase to his pre-transaction position. The transaction totaled $670,422.50. This purchase represents a material commitment of capital by a director and reflects a decision to expand his equity stake in the company at the prevailing market price.

Director James Huang purchased 19,335 shares of ATRA at $9.64, raising holdings to 1,350,000 shares

James Huang, a director at Atara Biotherapeutics, purchased 19,335 shares at $9.64 on 2025-07-17 for a total value of $186,372.00, increasing his holdings from 1,330,665 shares to 1,350,000 shares. The purchase represents a 1.5% increase relative to his pre-transaction holdings, a modest addition to an already substantial directorship position. This transaction reflects an incremental commitment to the company, though the relatively small scale of the acquisition relative to his existing 1.33M share base suggests a measured rather than aggressive positioning.